1/ $COV.AX (@cleodiagnostics), last close A$0.305, remains one of our highest-conviction holdings.
Today's inputs: CLEO's prototype ovarian cancer screening test cleared every pre-set target in its first proof of concept study (n=247, 62 Stage I cancers).
2/ The numbers. High-risk women, Stage I: 92.2% sensitivity / 98.7% specificity vs a 90/90 bar. General population: 75% / 100% vs 75% / 99.6%.
AUC 0.99 vs 0.83 for CA125 at Stage I. That is substantial outperformance, not a scrape over the line.
3/ This is not drug development. CLEO is a diagnostic on a 510(k) device pathway no Phase 1/2/3, no efficacy endpoint that can fail on a coin flip.
The questions are: does the assay reproduce, and does it perform in the intended population. Both are arguably becoming well evidenced ...
4/ A pattern of outperformance:
• 95% / 95% in a 334-patient cohort (peer-reviewed)
• Positive FDA feedback at two pre-sub meetings
• Pivotal US trial fully recruited (514 samples, 19 sites)
• MDSAP Stage 1 audit passed
• Today: screening targets cleared at Stage I
5/ Each result de-risks the next step. Analytical validation is underway on commercially manufactured kits. Clinical validation follows at Asuragen (Bio-Techne's CLIA lab). FDA 510(k) submission is targeted for early CY27.
6/ Market size, per the company:
• Triage: ~2.0M US women/yr, a $1.6B near-term entry point
• Screening: $150B+ global TAM
• Day-one US billing path already mapped (misc. CPT code 81599 post-clearance)
7/ Valuation at A$0.305: ~142M shares, market cap ≈ A$43M.
Strategics are pivoting to single cancer tests after NHS-Galleri missed. Abbott paid ~US$23B for Exact. Ovarian cancer has no approved screen.
8/ One more thing. CLEO's kit manufacturer, assay platform (Ella) and CLIA validation lab (Asuragen) are all Bio-Techne.
Bio-Techne is being acquired by Merck KGaA for US$11.3B, closing late 2026/early 2027. CLEO's whole supply chain is about to sit inside a global diagnostics group.
9/ Catalysts:
• Sept-quarter cash report (by 31 Oct)
• AV readout
• Screening panel locked by end CY26
• CV at Asuragen
• 510(k) submission H1 CY27
• Bridging cohort, then UKCTOCS/PLCO
Personal opinion only, not financial advice. Today's results are retrospective and need confirmation in larger cohorts. DYOR.
#ASX
$COV update. Since initiation at $0.17, we've seen a solid re-rate into $0.80s.
Now sits proudly alongside previous calls on $DXB <0.08, $ILA 0.06 & $NEU ~$1. @Cleodiagnostics team has been clinical in their execution, hitting key milestone on the path to commercialisation. 1/3
Replying to @Cleodiagnostics
@Cleodiagnostics a primer: $COV is a #ASX listed (market cap $21.7m, $9.973m cash EOQ for EV of $11.27m @ $0.17) medical diagnostics/devices company focussed on the development of non-invasive blood based IVD tests for detecting ovarian cancer presence & recurrence. 1/x
2
8
1,466
Execution has been "surgical'. Notably end 25 saw key KOL appointed US TAM uplift to 3.4M women/year. Crucially, this only covers the initial triage market— ignores the multi-billion $ population screening op being advanced in parallel w/ the UKCTOCS biobank & others 2/3
1
2
258
We now enter the most catalyst-rich period since IPO: completion of US triage trials & FDA submissions. Peer-reviewed data in the high profile scientific journal Cancers confirms $COVs substantial outperformance against the standard of care. Ref: doi.org/10.3390/cancers16112…. 3/3 #ASX
4
222
Big moment for @IslandPharma (ASX: $ILA, 0.55c open) We flagged this company back in August 2024 at ~6.1c — today’s annt of FDA acceptance of the Animal Rule pathway + Priority Review Voucher eligibility for galidesivir in Marburg is a pivotal de-risking of the regulatory path.
1/6 Island Pharmaceuticals a primer: ($ILA), an ASX-listed biotech company (Market Cap: $7.73M, EV: $6.07M @ 0.061), developing antiviral therapeutics for dengue fever and other mosquito-borne diseases. #ASX @IslandPharma
With peers eg SIGA (smallpox av+ US. govt stockpile contract) showing how animalrule/stockpile can translate into mc upside, potential for $ILA is sigt. If ILA secures US govt stockpile or realises the PRV through repeating prior results, we are looking at v meaningful re-rating.
2
339
$CVB’s TAM is sig't — ~A$10 billion in the US alone across
- Hospitals
- Imaging chains
- Surgeon group practices / ASCs
With ~17,000 potential installs, even modest penetration could be transformative. Now expanding TAM sig't with today’s binding JV w/ Weigao (~A$5b mc)
5/6
1
7
402
With strong clinical validation (Mayo Clinic, Mass General, HSS), reimbursement in major markets & new financing + distribution channels, $CVB looks to be entering its commercial scaling ph. From a ~$40mc > at a potential inflection pt - marrying proven tech w SaaS diags 6/6
6
432
sprout8.com retweeted
$WBE AE were LM on a small placement mainly to existing holders of Whitebark Energy. The Warro asset was always thought to have too much water. Enter Steve Adams, renowned petro-physicist, who has completed a totally independent re-evaluation.
Worth reading this closely.
Replying to @imagionbio
@imagionbio (ASX:IBX) interesting update:
– Ph2 HER2 breast cancer clinical supply manufacturing commenced
– AI imaging optimisation collaboration w/ Siemens & Wayne State Uni underway (initial results Sept ‘25)
– Ongoing FDA engagement, IND filing still targeted for H2 ‘25. $IBX
$ILA @IslandPharma's investor webinar Tuesday, 8 October 2024, at 10.30am AEDT for updates on ISLA-101 ph2 trial, Galidesivir acq, & strategic investment from the likes of Dr Daniel Tillett & prominent HK-based fund manager, Angus Walker. Register here: us02web.zoom.us/webinar/regi…
1/6 Island Pharmaceuticals a primer: ($ILA), an ASX-listed biotech company (Market Cap: $7.73M, EV: $6.07M @ 0.061), developing antiviral therapeutics for dengue fever and other mosquito-borne diseases. #ASX @IslandPharma
7
875
Replying to @IslandPharma
@IslandPharma update: Island Pharmaceuticals $ILA reports significant progress, achieving key milestones in its dengue fever clinical program and securing A$3.5 million to advance ISLA-101 and potentially acquire the promising antiviral, galidesivir. #dengue #ASX #biotech
1/6 Island Pharmaceuticals a primer: ($ILA), an ASX-listed biotech company (Market Cap: $7.73M, EV: $6.07M @ 0.061), developing antiviral therapeutics for dengue fever and other mosquito-borne diseases. #ASX @IslandPharma
With dosing commenced in its Ph 2a dengue trial & the acquisition of galidesivir (with over US$70M previously invested in its development) now funded, $ILA appears well-positioned. More detail on today’s announcements in this video interview below:
youtube.com/watch?v=t8JAvyBZ…
+video from Prof. Stephen Thomas explaining the challenges of developing effective dengue vaccines and treatments, the benefits of Island's approach with a human challenge study and potential opportunities for $ILA Phase 2 trial
youtube.com/watch?v=fnfZHYIW…
The trial will evaluate both therapeutic & prophylactic efficacy vs dengue. The design, available at clinicaltrials.gov/study/NCT… involves 14 participants & focuses on viral load reduction post subcutaneous challenge of healthy subjects with (DENV-1-LVHC). $ILA is now one to watch.
Replying to @sprout8com
3/6 Today's news marks a major milestone as $ILA get nod for revised Ph 2a/2b trial, partially funded by US Gov grant. Trial cost lower & results are expected in CY24. Pre-clinical trials were promising with 70% survival in ILA101-dosed group compared to 0% in the control group.


















